Syntax Advisors’s AbbVie ABBV Stock Holding History

Syntax Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$232K	Sell	1,558 -109	-7%	-$16K	0.2%	135
2023 Q2	$225K	Buy	1,667 +67	+4%	+$9.82K	0.18%	172
2023 Q1	$255K	Buy	1,600 +114	+8%	+$17.4K	0.19%	139
2022 Q4	$240K	Sell	1,486 -332	-18%	-$50.9K	0.2%	142
2022 Q3	$244K	Buy	1,818 +144	+9%	+$20.7K	0.21%	124
2022 Q2	$256K	Buy	1,674 +135	+9%	+$20.6K	0.22%	109
2022 Q1	$249K	Sell	1,539 -533	-26%	-$77.4K	0.21%	139
2021 Q4	$281K	Buy	+2,072	New	+$245K	0.21%	124

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Syntax Advisors's ABBV Position: Q3 2023 in Review

Syntax Advisors reduced its AbbVie (ABBV) stake by 6.5% in Q3 2023, selling an estimated $16K and leaving 1,558 shares worth $232K. The position accounts for 0.2% of the portfolio, ranked #135.

Syntax Advisors first reported a position in ABBV in Q4 2021 and has held it in 8 quarters since. The position peaked at $281K in Q4 2021. 3,108 funds tracked by Wall St. Rank hold ABBV as of Q3 2023.

Syntax Advisors held 1,558 shares of AbbVie worth $232K as of Q3 2023.
Syntax Advisors sold 109 AbbVie shares in Q3 2023, an estimated $16K.
AbbVie made up 0.2% of Syntax Advisors's portfolio in Q3 2023, its #135 holding.
Syntax Advisors first reported a position in AbbVie in Q4 2021 and has held it in 8 quarters since.
Syntax Advisors's AbbVie position peaked at $281K in Q4 2021.
3,108 funds tracked by Wall St. Rank held AbbVie as of Q3 2023.

Based on Syntax Advisors's 13F filing for Q3 2023, filed 13 Nov 2023.